MET and neoplasm: This study showed a dose-dependent specific tumour uptake of [89Zr]PRS-110 in the c-Met-expressing H441 (non-small cell lung cancer) and U87-MG (primary glioblastoma) tumours, whereas the uptake was lower (similar to non-specific control uptake) in the c-Met-negative A270 (ovarian cancer) tumour model.